MedKoo Cat#: 573440 | Name: Oxolamine hydrochloride

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Oxolamine hydrochloride is a cough suppressant which may be useful in the treatment of pediatric asthma.

Chemical Structure

Oxolamine hydrochloride
Oxolamine hydrochloride
CAS#1219-20-1 (HCl)

Theoretical Analysis

MedKoo Cat#: 573440

Name: Oxolamine hydrochloride

CAS#: 1219-20-1 (HCl)

Chemical Formula: C14H20ClN3O

Exact Mass: 281.1295

Molecular Weight: 281.78

Elemental Analysis: C, 59.67; H, 7.15; Cl, 12.58; N, 14.91; O, 5.68

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Synonym
683 M hydrochloride, AF 438 hydrochloride, Oxolamine HCl, Oxolamine hydrochloride
IUPAC/Chemical Name
1,2,4-Oxadiazole, 5-(2-(diethylamino)ethyl)-3-phenyl-, monohydrochloride
InChi Key
YHLIBHCNFDRYFW-UHFFFAOYSA-N
InChi Code
1S/C14H19N3O.ClH/c1-3-17(4-2)11-10-13-15-14(16-18-13)12-8-6-5-7-9-12;/h5-9H,3-4,10-11H2,1-2H3;1H
SMILES Code
c1(c2ccccc2)nc(CC[NH+](CC)CC)on1.[ClH-]
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 281.78 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Wang XQ, Wang XM, Zhou TF, Dong LQ. Screening of differentially expressed genes and small molecule drugs of pediatric allergic asthma with DNA microarray. Eur Rev Med Pharmacol Sci. 2012 Dec;16(14):1961-6. PubMed PMID: 23242723. 2: Zhu X, Lee DY, Shin WG. Gender difference in the pharmacokinetic interaction between oral warfarin and oxolamine in rats: inhibition of CYP2B1 by oxolamine in male rats. Biopharm Drug Dispos. 2007 Apr;28(3):125-33. PubMed PMID: 17295362. 3: Min KA, Zhu X, Oh JM, Shin WG. Effect of oxolamine on anticoagulant effect of warfarin. Am J Health Syst Pharm. 2006 Jan 15;63(2):153-6. PubMed PMID: 16390929. 4: Ceyhan BB, Karakurt S. Effect of oxolamine on cough sensitivity in COPD patients. Respir Med. 2002 Jan;96(1):61-3. PubMed PMID: 11863211. 5: Kirilmaz L, Kendirci A, Güneri T. Sustained-release dosage form of oxolamine citrate: preparation and release kinetics. J Microencapsul. 1992 Apr-Jun;9(2):167-72. PubMed PMID: 1593399. 6: Meyboom RH. Adverse reaction to drugs in children, experiences with "spontaneous monitoring" in The Netherlands. Bratisl Lek Listy. 1991 Nov;92(11):554-9. PubMed PMID: 1806168. 7: McEwen J, Meyboom RH, Thijs I. Hallucinations in children caused by oxolamine citrate. Med J Aust. 1989 Apr 17;150(8):449-50, 452. PubMed PMID: 2716683. 8: Gunella G, Fabbri M, Laghi M. [Therapeutic action of oxolamine in acute tracheo-bronchitis]. Clin Ter. 1982 Mar 15;100(5):485-92. Italian. PubMed PMID: 7140166. 9: Cerqua R, Trovello C, Infante G, Ricciardi S. [The use of guacetisal in chronic obstructive bronchopneumopathy. Controlled clinical study]. Minerva Med. 1981 Feb 28;72(7):355-62. Italian. PubMed PMID: 7017485. 10: Canela R, Calzon A, Taxonera F. [Use of photodensitometry in the control of pharmaceutical products. Evaluation of a mixture of 3 amines: oxolamine camphosulfonate, diphenhydramine hydrochloride and methoxyphenamine hydrocholoride]. Boll Chim Farm. 1975 Apr;114(4):201-5. Spanish. PubMed PMID: 1131323. 11: Cairella M. [Associations of antibiotics with non-steroid anti-inflammatory agents. Clinical observations on the treatment of acute and chronic bronchitis with tetracycline-oxolamine]. Policlinico Prat. 1970 Sep 14;77(37):1183-6. Italian. PubMed PMID: 5458803. 12: Silvestrini B. [Use of anti-inflammatory agents, particularly oxolamine and benzydamine, in respiratory diseases]. Brux Med. 1970 Mar;50(3):204-10. French. PubMed PMID: 5446622. 13: Cairella M. [Combinations of antibiotics with non-steroidal anti-inflammatory agents. Clinical study of treatment of acute and chronic bronchitis with tetracycline-oxolamine]. Clin Ter. 1969 Nov 15;51(3):221-6. Italian. PubMed PMID: 5407317. 14: Dalhamn T. The anticiliostatic effect of cigarettes treated with oxolamine citrate. Am Rev Respir Dis. 1969 Mar;99(3):447-8. PubMed PMID: 5765637. 15: Cosi G. [Colorimetric determination of oxolamine citrate]. Boll Chim Farm. 1968 Oct;107(10):636-9. Italian. PubMed PMID: 5729788. 16: Raveau MJ. [Association of an antibiotic, tetracycline hydrochloride with an antiedemic agent, oxolamine benzylate, in pediatric therapy]. Lyon Med. 1968 Jul 7;219(27):23-31. French. PubMed PMID: 5742617. 17: Gaudier B, Ryckewaert P. [Use of oxolamine cycline benzylate in pediatrics]. Lille Med. 1968 Mar;13(3):Suppl:269-72. French. PubMed PMID: 5759687. 18: Dalhamn T, Raud A. The antitussive effect of oxolamine citrate and codeine phosphate in guinea pigs. Scand J Respir Dis. 1968;49(1):23-5. PubMed PMID: 5187247. 19: Campan ML. [Preparation for bronchospirometry; value of an anti-inflammatory substance: oxolamine citrate]. Lyon Med. 1967 Sep 17;217(38):469-75. French. PubMed PMID: 5622032. 20: Rusconi R, Reggiani A. [Clinical study on the action of oxolamine (Perebron) on inflammatory diseases of the urinary tract]. Minerva Urol. 1967 Mar-Apr;19(2):66-71. Italian. PubMed PMID: 5607079.